What is the 13F Pro Quality Score for CVM?

13F Pro ranks CEL SCI CORP (CVM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CVM's current score at https://13fpro.ai/company/CVM (free sign-up required for the full ranking).

Where does 13F Pro source CVM data?

All CEL SCI CORP fundamentals and ownership data come directly from SEC EDGAR. CEL SCI CORP files with the SEC under CIK 725363. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CVM in?

CEL SCI CORP (CVM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CVM research updated on 13F Pro?

CVM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CEL SCI CORP(CVM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 725363 CVM stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

CVM Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for CEL SCI CORP (CVM), a Healthcare sector company. CVM is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), CEL SCI CORP reports net income of $-5.7M, free cash flow of $-4.0M. Top institutional holders of CVM by reported 13-F value include RENAISSANCE TECHNOLOGIES, VANGUARD CAPITAL MANAGEMENT, CITADEL ADVISORS, based on the most recent SEC filings. CVM trades on the NYSE exchange and files with the SEC under CIK 725363. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CVM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CEL SCI CORP directly from SEC EDGAR.

✦

Fun facts about CEL SCI CORP

Quirks, history, and lore behind CVM — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · micro-cap · listed on NYSE American · headquartered in Virginia.
2
The Numbers
Revenue is minimal — as with most clinical-stage biotechs, the company runs on grants and equity raises rather than product sales, keeping it in perpetual early-stage territory.
3
The History
Founded in the 1980s, the company has spent decades pursuing a single audacious goal: teaching the immune system to fight cancer and infectious disease rather than using conventional drugs.
4
The Secret
Its core platform is built around Multikine, an investigational immunotherapy cocktail of natural cytokines intended to prime the immune system before surgery in head and neck cancer patients.
5
The Lore
The company has been running a Phase 3 clinical trial for Multikine for an extraordinarily long time — long enough that investors have dubbed it one of biotech's longest-running trials of its kind.
6
The Giveaway
Ticker CVM, the lone product is Multikine, and the company's full name literally stands for CEL-SCI — a nod to cellular immunology being its entire reason for existing.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-5.7M

Free Cash Flow

Q2 2026

$-4.0M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

+5.6% YoY

$-25.4MFY 2025

FY22 $-36.7MFY23 $-32.4MFY24 $-26.9MFY25 $-25.4M

Operating Income

+5.9% YoY

$-24.8MFY 2025

FY22 $-36.1MFY23 $-31.5MFY24 $-26.4MFY25 $-24.8M

EPS (Diluted)

+59.0% YoY

$-6.27FY 2025

FY22 $-0.87FY23 $-0.73FY24 $-15.31FY25 $-6.27

Total Assets

+4.3% YoY

$28.2MFY 2025

FY22 $50.5MFY23 $30.5MFY24 $27.0MFY25 $28.2M

Total Debt

$8.0MFY 2025

FY22 —FY23 —FY24 —FY25 $8.0M

Op. Cash Flow

+9.0% YoY

$-17.1MFY 2025

FY22 $-18.2MFY23 $-22.8MFY24 $-18.8MFY25 $-17.1M

Free Cash Flow

+9.2% YoY

$-17.2MFY 2025

FY22 $-18.9MFY23 $-23.2MFY24 $-18.9MFY25 $-17.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-25.4M +5.6%	$-26.9M +16.8%	$-32.4M +11.8%	$-36.7M -0.9%	$-36.4M -20.2%	$-30.3M
Operating Income	$-24.8M +5.9%	$-26.4M +16.3%	$-31.5M +12.7%	$-36.1M +0.4%	$-36.2M -24.9%	$-29.0M
EPS (Diluted)	$-6.27 +59.0%	$-15.31 -1997.3%	$-0.73 +16.1%	$-0.87 +3.3%	$-0.90 -9.8%	$-0.82
Total Assets	$28.2M +4.3%	$27.0M -11.6%	$30.5M -39.6%	$50.5M -33.4%	$75.9M +87.2%	$40.5M
Total Debt	$8.0M	—	—	—	—	—
Operating Cash Flow	$-17.1M +9.0%	$-18.8M +17.7%	$-22.8M -25.3%	$-18.2M +2.9%	$-18.8M -23.0%	$-15.3M
Free Cash Flow	$-17.2M +9.2%	$-18.9M +18.5%	$-23.2M -22.9%	$-18.9M +32.1%	$-27.8M -55.1%	$-17.9M

AI Insight: CVM Financial Trends

Pre-revenue biotech burning $4–6M quarterly with equity base eroding; no clear path to cash flow inflection visible.

• Net income losses narrowed from $7M (Q4 2024) to $5M (Q4 2025, Q1 2026), suggesting modest cost control.

• Operating cash burn remained flat at $4–5M per quarter across all eight quarters; no improvement trend.

• Equity base contracted 46% from $13M (Q3 2024) to $7M (Q1 2026), signaling ongoing dilution and balance-sheet pressure.

⚠ Debt appeared Q3 2025 ($8M), then vanished from subsequent quarters—clarify refinancing/repayment status and impact on runway.

⚠ Zero revenue across all periods indicates clinical-stage status; cash runway at current burn is critical inflection point.

AI Insight: CVM Ratio Trends

CEL SCI lacks sufficient profitability data to assess operational trends; available ROE and ROA metrics show persistent deep losses.

• ROE deteriorated from -189.9% in Q3 2024 to -196.4% in Q4 2025, indicating worsening shareholder value destruction.

• ROA improved slightly from -90.5% in Q3 2024 to -86.7% in Q3 2025, though still deeply negative.

• D/E ratio of 0.50 in Q3 2025 suggests moderate leverage; insufficient data to assess debt trend.

⚠ Consistently negative ROE and ROA across all reported quarters indicate sustained unprofitability; no path to positive returns visible.

⚠ OpMargin, NPM, and ROIC data entirely absent; inability to assess operational efficiency or cost structure.

Get alerted when CVM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CEL SCI CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CVM

RENAISSANCE TECHNOLOGIES LLC
$595.4K572,460 sh
VANGUARD CAPITAL MANAGEMENT LLC
$564.8K543,079 sh
CITADEL ADVISORS LLC
$206.4K198,500 sh
MAI Capital Management
$112.6K108,280 sh
GEODE CAPITAL MANAGEMENT, LLC
$91.8K88,200 sh
COMMONWEALTH EQUITY SERVICES, LLC
$53.5K51,434 sh
HRT FINANCIAL LP
$53.0K51,155 sh
VANGUARD FIDUCIARY TRUST CO
$51.0K49,036 sh
BlackRock, Inc.
$45.0K43,261 sh
BANK OF AMERICA CORP /DE/
$42.6K40,916 sh

Fund	Value	Shares
RENAISSANCE TECHNOLOGIES LLC	$595.4K	572,460
VANGUARD CAPITAL MANAGEMENT LLC	$564.8K	543,079
CITADEL ADVISORS LLC	$206.4K	198,500
MAI Capital Management	$112.6K	108,280
GEODE CAPITAL MANAGEMENT, LLC	$91.8K	88,200
COMMONWEALTH EQUITY SERVICES, LLC	$53.5K	51,434
HRT FINANCIAL LP	$53.0K	51,155
VANGUARD FIDUCIARY TRUST CO	$51.0K	49,036
BlackRock, Inc.	$45.0K	43,261
BANK OF AMERICA CORP /DE/	$42.6K	40,916

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CVM on your watchlist

Track score changes the day CEL SCI CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CVM a good stock to buy?

13F Pro's AI-powered analysis of CEL SCI CORP (CVM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CVM are available on the CVM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CVM is classified as a small company.

Which hedge funds own CVM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CVM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CEL SCI CORP's investment landscape.